Jump to content

Drilldown: Medicines

Pharmacopedia is being built in public. Pages may be incomplete.About this site

Nav

Choose a table:

Medicines (732)

Medicines > classes

: Classic Psychedelic

or Empathogen

or [[:Category:Basal_insulins|Basal insulin]]

Use the filters below to narrow your results.

None (83) · Delysid (historical, Sandoz, withdrawn 1965) (1) · Lantus, Basaglar, Semglee, Toujeo (U-300) (1) · Levemir, Levemir FlexTouch (US discontinuation announced 2024) (1) · Tresiba (1)

5-HT2A agonist (26) · Potent 5-HT2A agonist (5) · LSD analogue; 5-HT2A agonist (4) · Prodrug of LSD; 5-HT2A agonist (4) · Monoamine releasing agent (3) · Serotonin releasing agent; 5-HT2A agonist (3) · Serotonin/norepinephrine/dopamine releasing agent (3) · Contains LSA (2) · Contains mescaline (2) · Serotonin releasing agent (2)

Other values:

None (84) · '"`UNIQ--vote-00000239-QINU`"', '"`UNIQ--vote-0000023A-QINU`"' (1) · '"`UNIQ--vote-00001358-QINU`"', '"`UNIQ--vote-00001359-QINU`"' (1) · '"`UNIQ--vote-00001372-QINU`"', '"`UNIQ--vote-00001373-QINU`"' (1)

None (84) · ~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose (2) · ~10 units SC at the same time daily, or 0.1-0.2 units/kg/d; titrate by fasting glucose. Frequently dosed BID at moderate-to-high doses (1)

None (84) · 100 U/mL (FlexTouch pen) and 200 U/mL (FlexTouch pen, higher-dose convenience) (1) · 100 U/mL (Lantus, Basaglar, Semglee) vials and pens; 300 U/mL (Toujeo) pens (1) · 100 U/mL FlexTouch pen, vial (1)

None (84) · Titrated to glucose (1) · Titrated to glucose; no fixed ceiling (2)

None (83) · Oral (1) · Subcutaneous (1) · Subcutaneous (never IV; not for use in insulin pumps) (2)

None (83) · 1-2 hours (2) · 30–60 minutes (1) · ~1 hour (1)

None (83) · 8–12 hours (1) · >42 hours per dose (effectively flat once at steady state) (1) · ~12-24 hours (dose-dependent; BID dosing often needed at higher doses) (1) · ~24 hours per dose (peakless profile by design) (1)

None (83) · 3–5 hours (1) · ~12 hours apparent (functional duration ~24 hours due to depot release kinetics)'"`UNIQ--ref-0000023B-QINU`"' (1) · ~25 hours apparent (functional duration well over 42 hours from multi-hexamer depot)'"`UNIQ--ref-0000135A-QINU`"' (1) · ~7 hours apparent'"`UNIQ--ref-00001374-QINU`"' (1)

None (83) · 70–90% (oral) (1) · ~100% from subcutaneous depot (1) · ~100% from subcutaneous depot (by definition of the route) (1) · ~60% from subcutaneous depot (reduced by reversible albumin binding via the myristic acid side chain that also extends duration)'"`UNIQ--ref-00001375-QINU`"' (1)

None (83) · Insulin is the preferred glucose-lowering therapy in pregnancy; degludec has reassuring observational data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Insulin is the preferred glucose-lowering therapy in pregnancy; glargine has reassuring observational data, though NPH and detemir remain the traditional choices.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) · Not established (1) · One of the better-studied basal insulin analogs in pregnancy; reassuring data.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)

None (83) · Schedule I (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US (3)

Showing below up to 89 results in range #1 to #89.

1

2

4

4-HO-MiPT

5

6

6-APB
6-APDB

A

B

D

E

H

Hawaiian Baby Woodrose

I

Insulin Degludec

L

M

P

S

San Pedro cactus

T

TMA-2

Y

Yopo

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"